Escitalopram

Generic Name
Escitalopram
Brand Names
Cipralex, Lexapro
Drug Type
Small Molecule
Chemical Formula
C20H21FN2O
CAS Number
128196-01-0
Unique Ingredient Identifier
4O4S742ANY
Background

Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with...

Indication

Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disor...

Associated Conditions
Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)
Associated Therapies
-
Clinical Trials
Related News

Study of Neural Responses Induced by Antidepressant Effects

First Posted Date
2016-02-04
Last Posted Date
2022-11-03
Lead Sponsor
Marta Peciña, MD PhD
Target Recruit Count
60
Registration Number
NCT02674529
Locations
🇺🇸

WPIC, Pittsburgh, Pennsylvania, United States

The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients

Phase 2
Conditions
GBM
Depression
Interventions
Drug: Escitalopram
Drug: placebo
First Posted Date
2015-12-07
Last Posted Date
2015-12-07
Lead Sponsor
Tel-Aviv Sourasky Medical Center
Target Recruit Count
100
Registration Number
NCT02623231
Locations
🇮🇱

The Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Advancing Personalized Antidepressant Treatment Using PET/MRI

Phase 4
Completed
Conditions
Depression
Interventions
Drug: Placebo
Drug: Escitalopram
First Posted Date
2015-12-07
Last Posted Date
2022-12-15
Lead Sponsor
Stony Brook University
Target Recruit Count
85
Registration Number
NCT02623205
Locations
🇺🇸

Stony Brook University Hospital, Stony Brook, New York, United States

SSRI Effects on Depression and Immunity in HIV/AIDS

Phase 4
Completed
Conditions
Depression
AIDS
HIV
Interventions
Drug: Escitalopram
Other: Placebo
First Posted Date
2015-12-02
Last Posted Date
2024-05-07
Lead Sponsor
University of Pennsylvania
Target Recruit Count
108
Registration Number
NCT02620150
Locations
🇺🇸

University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States

Mechanism of Antidepressant-Related Dysfunctional Arousal in High-Risk Youth

First Posted Date
2015-09-17
Last Posted Date
2024-02-26
Lead Sponsor
University of Cincinnati
Target Recruit Count
214
Registration Number
NCT02553161
Locations
🇺🇸

Stanford University, Stanford, California, United States

🇺🇸

University of Cincinnati, Cincinnati, Ohio, United States

Exercise and Pharmacotherapy for Anxiety in Cardiac Patients

First Posted Date
2015-08-05
Last Posted Date
2021-06-11
Lead Sponsor
Duke University
Target Recruit Count
128
Registration Number
NCT02516332
Locations
🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

The Effect of Patient and Investigator Expectation on the Efficacy of Escitalopram in the Treatment Depression

Not Applicable
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: Escitalopram
First Posted Date
2015-06-24
Last Posted Date
2015-06-24
Lead Sponsor
Abarbanel Mental Health Center
Target Recruit Count
52
Registration Number
NCT02480400
Locations
🇮🇱

Abarbanel MHC, Bat-Yam, Israel

Effect of Lactobacillus Plantarum 299v Supplementation on Major Depression Treatment

First Posted Date
2015-06-11
Last Posted Date
2018-09-07
Lead Sponsor
Medical University of Bialystok
Target Recruit Count
60
Registration Number
NCT02469545
Locations
🇵🇱

Department of Psychiatry, Medical University of Bialystok, Bialystok, Poland

The Routine Use of SSRI's at the Initiation of End-stage Renal Disease Treatment (RoSIE)

Phase 2
Terminated
Conditions
End Stage Renal Disease
Interventions
Drug: Escitalopram
Drug: Placebo
First Posted Date
2015-04-03
Last Posted Date
2018-10-11
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
25
Registration Number
NCT02407821
Locations
🇨🇦

St. Michael's Hospital, Toronto, Ontario, Canada

🇨🇦

University Health Network, Toronto, Ontario, Canada

🇨🇦

St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada

Pharmacovigilance in Gerontopsychiatric Patients

Phase 3
Terminated
Conditions
Dementia
Depression
Schizophrenia
Psychosomatic Disorders
Anxiety Disorders
Interventions
Drug: Phenobarbital
Drug: Phenytoin
Drug: Carbamazepine
Drug: Oxcarbazepine
Drug: Valproic Acid
Drug: Lamotrigine
Drug: Topiramate
Drug: Gabapentin
Drug: Levetiracetam
Drug: Pregabalin
Drug: Lacosamide
Drug: Clonazepam
Drug: Biperiden
Drug: Levomepromazine
Drug: Fluphenazine
Drug: Perphenazine
Drug: Perazine
Drug: Thioridazine
Drug: Haloperidol
Drug: Melperone
Drug: Pipamperone
Drug: Bromperidol
Drug: Benperidol
Drug: Sertindole
Drug: Ziprasidone
Drug: Flupentixol
Drug: Chlorprothixene
Drug: Zuclopenthixol
Drug: Fluspirilene
Drug: Pimozide
Drug: Clozapine
Drug: Olanzapine
Drug: Quetiapine
Drug: Sulpiride
Drug: Tiapride
Drug: Amisulpride
Drug: Prothipendyl
Drug: Risperidone
Drug: Aripiprazole
Drug: Paliperidone
Drug: Diazepam
Drug: Oxazepam
Drug: Lorazepam
Drug: Bromazepam
Drug: Clobazam
Drug: Alprazolam
Drug: Hydroxyzine
Drug: Buspirone
Drug: Chloral Hydrate
Drug: Flurazepam
Drug: Nitrazepam
Drug: Triazolam
Drug: Lormetazepam
Drug: Temazepam
Drug: Midazolam
Drug: Brotizolam
Drug: Zopiclone
Drug: Zolpidem
Drug: Zaleplon
Drug: Melatonin
Drug: Clomethiazole
Drug: Diphenhydramine
Drug: Promethazine
Drug: Imipramine
Drug: Clomipramine
Drug: Opipramol
Drug: Trimipramine
Drug: Amitriptyline
Drug: Nortriptyline
Drug: Doxepin
Drug: Maprotiline
Drug: Amitriptyline oxide
Drug: Fluoxetine
Drug: Citalopram
Drug: Paroxetine
Drug: Sertraline
Drug: Fluvoxamine
Drug: Escitalopram
Drug: Tranylcypromine
Drug: Moclobemide
Drug: Mianserin
Drug: Trazodone
Drug: Mirtazapine
Drug: Bupropion
Drug: Venlafaxine
Drug: Reboxetine
Drug: Duloxetine
Drug: Agomelatine
Drug: Pyritinol
Drug: Piracetam
Drug: Donepezil
Drug: Rivastigmine
Drug: Galantamine
Drug: Memantine
Drug: Nicergoline
Drug: Acamprosate
Drug: Lithium
First Posted Date
2015-03-02
Last Posted Date
2018-02-28
Lead Sponsor
Hannover Medical School
Target Recruit Count
407
Registration Number
NCT02374567
Locations
🇩🇪

Bezirkskrankenhaus Augsburg, Augsburg, Germany

🇩🇪

Krankenhaus Hedwigshöhe, Berlin, Germany

🇩🇪

Hannover Medical School, Hannover, Germany

and more 2 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy